Armata Pharmaceuticals Stock Performance
| ARMP Stock | USD 1.82 0.03 1.68% |
The firm shows a Beta (market volatility) of -0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Armata Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Armata Pharmaceuticals is likely to outperform the market. At this point, Armata Pharmaceuticals has a negative expected return of -0.15%. Please make sure to confirm Armata Pharmaceuticals' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Armata Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest abnormal performance, the Stock's primary indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Last Split Factor 1:14 | Dividend Date 2019-05-10 | Last Split Date 2019-05-10 |
1 | Insider Trading | 01/02/2025 |
2 | Acquisition by Peterson Todd C. of 28000 shares of Armata Pharmaceuticals at 4.29 subject to Rule 16b-3 | 01/03/2025 |
3 | Armata Pharmaceuticals, Inc. Short Interest Update - MarketBeat | 01/30/2025 |
4 | Acquisition by Birx Deborah of 240000 shares of Armata Pharmaceuticals at 2.04 subject to Rule 16b-3 | 02/05/2025 |
5 | Acquisition by Odysseas Kostas D of 54343 shares of Armata Pharmaceuticals at 2.04 subject to Rule 16b-3 | 02/07/2025 |
6 | Acquisition by Haimovitz Jules of 666 shares of Armata Pharmaceuticals at 3.38 subject to Rule 16b-3 | 02/12/2025 |
7 | Armata Pharmaceuticals Secures 10M Loan for Clinical Trials - TipRanks | 03/12/2025 |
8 | Acquisition by Odysseas Kostas D of 54343 shares of Armata Pharmaceuticals at 3.38 subject to Rule 16b-3 | 03/14/2025 |
9 | Armata Pharmaceuticals Inc Q4 2024 Earnings EPS of 0.07 Beats Estimates, Revenue of 1. ... | 03/21/2025 |
| Begin Period Cash Flow | 19.2 M |
Armata |
Armata Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 204.00 in Armata Pharmaceuticals on December 24, 2024 and sell it today you would lose (25.00) from holding Armata Pharmaceuticals or give up 12.25% of portfolio value over 90 days. Armata Pharmaceuticals is currently does not generate positive expected returns and assumes 3.4868% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Armata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Armata Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Armata Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Armata Pharmaceuticals, and traders can use it to determine the average amount a Armata Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARMP |
Estimated Market Risk
| 3.49 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Armata Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Armata Pharmaceuticals by adding Armata Pharmaceuticals to a well-diversified portfolio.
Armata Pharmaceuticals Fundamentals Growth
Armata Stock prices reflect investors' perceptions of the future prospects and financial health of Armata Pharmaceuticals, and Armata Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Armata Stock performance.
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 181.99 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 4.06 X | ||||
| Price To Sales | 11.85 X | ||||
| Revenue | 5.47 M | ||||
| Gross Profit | (28.05 M) | ||||
| EBITDA | (42.44 M) | ||||
| Net Income | (18.92 M) | ||||
| Cash And Equivalents | 36.98 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 71.08 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | (1.41) X | ||||
| Cash Flow From Operations | (37.55 M) | ||||
| Earnings Per Share | (0.89) X | ||||
| Market Capitalization | 64.77 M | ||||
| Total Asset | 86.44 M | ||||
| Retained Earnings | (327.74 M) | ||||
| Working Capital | 2.69 M | ||||
| Current Asset | 4.48 M | ||||
| Current Liabilities | 4.08 M | ||||
About Armata Pharmaceuticals Performance
Assessing Armata Pharmaceuticals' fundamental ratios provides investors with valuable insights into Armata Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Armata Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (49.06) | (51.51) | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (1.11) | (1.17) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | 0.39 | 0.41 |
Things to note about Armata Pharmaceuticals performance evaluation
Checking the ongoing alerts about Armata Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Armata Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Armata Pharmaceuticals generated a negative expected return over the last 90 days | |
| Armata Pharmaceuticals may become a speculative penny stock | |
| Armata Pharmaceuticals has high historical volatility and very poor performance | |
| Armata Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5.47 M. Net Loss for the year was (18.92 M) with loss before overhead, payroll, taxes, and interest of (28.05 M). | |
| Armata Pharmaceuticals currently holds about 36.98 M in cash with (37.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Armata Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Armata Pharmaceuticals Inc Q4 2024 Earnings EPS of 0.07 Beats Estimates, Revenue of 1. ... |
- Analyzing Armata Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Armata Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Armata Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Armata Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Armata Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Armata Pharmaceuticals' stock. These opinions can provide insight into Armata Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.